Cargando…
Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021
During 2020 and 2021, the COVID-19 pandemic has resulted in interruptions and cancellations of clinical trials and has delayed drug development in all areas except SARS-CoV-2 vaccine development. A further concern is the need to rapidly share anonymized datasets and improve opportunities to conduct...
Autor principal: | Parums, Dinah V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415037/ https://www.ncbi.nlm.nih.gov/pubmed/34456331 http://dx.doi.org/10.12659/MSM.934514 |
Ejemplares similares
-
In Extenuation
Publicado: (1887) -
Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein
por: Parums, Dinah V.
Publicado: (2021) -
Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021) -
Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD)
por: Parums, Dinah V.
Publicado: (2021) -
Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution
por: Parums, Dinah V.
Publicado: (2023)